Non-alcoholic Fatty Liver Disease
"Non-alcoholic Fatty Liver Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Descriptor ID |
D065626
|
| MeSH Number(s) |
C06.552.241.519
|
| Concept/Terms |
Non-alcoholic Fatty Liver Disease- Non-alcoholic Fatty Liver Disease
- Non alcoholic Fatty Liver Disease
- NAFLD
- Nonalcoholic Fatty Liver Disease
- Fatty Liver, Nonalcoholic
- Fatty Livers, Nonalcoholic
- Liver, Nonalcoholic Fatty
- Livers, Nonalcoholic Fatty
- Nonalcoholic Fatty Liver
- Nonalcoholic Fatty Livers
Nonalcoholic Steatohepatitis- Nonalcoholic Steatohepatitis
- Nonalcoholic Steatohepatitides
- Steatohepatitides, Nonalcoholic
- Steatohepatitis, Nonalcoholic
|
Below are MeSH descriptors whose meaning is more general than "Non-alcoholic Fatty Liver Disease".
Below are MeSH descriptors whose meaning is more specific than "Non-alcoholic Fatty Liver Disease".
This graph shows the total number of publications written about "Non-alcoholic Fatty Liver Disease" by people in this website by year, and whether "Non-alcoholic Fatty Liver Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 6 | 6 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 7 | 0 | 7 |
| 2016 | 10 | 2 | 12 |
| 2017 | 13 | 1 | 14 |
| 2018 | 16 | 0 | 16 |
| 2019 | 20 | 2 | 22 |
| 2020 | 13 | 0 | 13 |
| 2021 | 18 | 1 | 19 |
| 2022 | 17 | 0 | 17 |
| 2023 | 34 | 0 | 34 |
| 2024 | 8 | 1 | 9 |
| 2025 | 5 | 0 | 5 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Non-alcoholic Fatty Liver Disease" by people in Profiles.
-
Dietary Vitamin D Insufficiency Aggravates High-Fat Diet-Induced Hepatic Steatosis Associated with Reduced Hepatic SIRT1 Activity and Nrf2-Related Antioxidant Gene Expression in Male C57BL/6J Mice. Nutrients. 2026 Jul 31; 18(15).
-
Vertical Sleeve Gastrectomy Versus Comprehensive Lifestyle Intervention for Adolescents With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Controlled Cohort Study. Aliment Pharmacol Ther. 2026 Sep; 64(6):758-769.
-
Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis. Med. 2026 May 08; 7(5):101077.
-
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. Nat Rev Gastroenterol Hepatol. 2026 Jun; 23(6):460-474.
-
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study. Lancet Gastroenterol Hepatol. 2026 Mar; 11(3):232-242.
-
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Aliment Pharmacol Ther. 2025 Dec; 62(11-12):1089-1099.
-
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025 Jun 26; 392(24):2413-2424.
-
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 05; 392(21):2089-2099.
-
Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment. Clin Mol Hepatol. 2025 Jul; 31(3):753-770.
-
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Curr Diab Rep. 2024 Nov 13; 25(1):5.